Takuya Yamada

Takuya Yamada

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
EKEiji Kimura
Eiji Kimura
SASumiko Abe
Sumiko Abe
TTTakashi Tanimoto
Takashi Tanimoto
KOKohsaku Ohnishi
Kohsaku Ohnishi
NHNaoki Hiramatsu
Naoki Hiramatsu
Zinc plays a pivotal role in various zinc enzymes, which are crucial in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. Whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development remains unknown. Two hundred and sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients), were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were observed to be lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p < 0.001). According to serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dL (p < 0.001). Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dL.

20 February 2024 in Digestive Endoscopy
Verified
Journal Article
Open access
HOHideharu Ogiyama
Hideharu Ogiyama
MKMinoru Kato
Minoru Kato
SYShinjiro Yamaguchi
Shinjiro Yamaguchi
TKTakashi Kanesaka
Takashi Kanesaka
TYTakuya Yamada
Takuya Yamada
TTTetsuo Takehara
Tetsuo Takehara
Objectives: The high rate of delayed bleeding after colorectal endoscopic submucosal dissection (ESD) in patients undergoing anticoagulant therapy remains a problem. Whether prophylactic clip closure reduces the rate of delayed bleeding in these patients is unclear. This study aimed to evaluate the efficacy of prophylactic clip closure in patients receiving anticoagulants.Methods: This multicenter prospective interventional trial was conducted at nine referral centers in Japan. Patients regularly taking anticoagulants, including warfarin potassium or direct oral anticoagulants, and undergoing ESD for colorectal neoplasms were enrolled. The discontinuation of anticoagulants was minimized according to recent guidelines. After the ESD, post‐ESD ulcers were prophylactically closed using endoclips. The primary end‐point was the incidence of delayed bleeding. The sample size was 45 lesions, and prophylactic clip closure was considered effective when the upper limit of the 90% confidence interval (CI) for delayed bleeding did not exceed 20%.Results: Forty‐five lesions were used, and three were excluded. Complete closure was achieved in 41/42 lesions (97.6%). The overall delayed bleeding rate was low, at 4.9% (2/41; 90% [CI] 0.8–14.5), which was significantly lower than that at the prespecified threshold of 20% (P = 0.007). The median closure procedure time was 17 min, and the median number of clips was nine. No massive delayed bleeding requiring transfusion, interventional radiology, or surgery was observed, and no thromboembolic events were observed.Conclusion: Prophylactic clip closure may reduce the risk of delayed bleeding following colorectal ESD in patients receiving anticoagulants.Trial registration: UMIN Clinical Trial Registry (UMIN000036734).

22 October 2018 in Preprints.org
Verified
Preprint
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
EKEiji Kimura
Eiji Kimura
SASumiko Abe
Sumiko Abe
TTTakashi Tanimoto
Takashi Tanimoto
KOKohsaku Ohnishi
Kohsaku Ohnishi
NHNaoki Hiramatsu
Naoki Hiramatsu
Background and Aim: Zinc plays a pivotal role in various zinc enzymes, resulting in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. It remains unknown whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development. Patients and Methods: Two hundred sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients) were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Results: Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p<0.001). According to the serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dl (p<0.001). Conclusion: Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dl.

11 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NHNaoko Hayata
Naoko Hayata
AHAtsushi Hosui
Atsushi Hosui
TKTomohide Kurahashi
Tomohide Kurahashi
SSShigeki Suemura
Shigeki Suemura
ANAkane Namiki
Akane Namiki
NHNaoki Hiramatsu
Naoki Hiramatsu
Background: Liver function is a critical factor, both in the selection of treatment and in the prediction of prognosis in patients with hepatocellular carcinoma (HCC). The ALBI grade, introduced as a more objective method of assessing liver function, utilizes serum albumin (Alb) and total bilirubin (Bil) levels. Although albumin is widely recognized for its role in maintaining colloid osmotic pressure and regulating plasma volume, recent studies have implicated it in tumor progression, invasion, and metastasis. The purpose of this study is to determine the impact of serum albumin levels on overall survival (OS) and tumor invasion/metastasis in HCC patients with the same liver function (ALBI grade) at the time of diagnosis. Methods: In this study, 285 patients diagnosed with primary HCC at our institution from 2015 to 2019 were classified by ALBI grade and analyzed. Among them, 78 patients with ALBI grade 2 status were selected to evaluate the impact of albumin level. To further isolate the effect of albumin rather than bilirubin, patients in the ALBI grade 2 cohort were divided into two groups based on mean values of Alb (3.5 g/dL) and Bil (1.0 mg/dL). Alb normal group (Group A): Alb ≥ 3.5 g/dL, Bil ≥ 1.0 mg/dL (n = 42). Bil normal group (Group T): Alb < 3.5 g/dL, Bil < 1.0 mg/dL (n = 36). Liver function was almost the same in these two groups based on the ALBI grade. OS, progression-free survival (PFS), types of recurrence, and pathological findings were compared between the two groups. OS was analyzed by the log-rank test, and comparisons between the two groups were performed by the t-test and chi-square test, with p < 0.05 indicating statistical significance. Results: OS was significantly worse in Group T than in Group A before and after propensity score matching based on age, performance status, and HCC stage (p < 0.001 and p = 0.011). Among the 44 patients who received curative treatment (surgery or radiofrequency ablation), OS was also significantly worse in Group T (p < 0.001). An analysis of the recurrence patterns of 44 curatively treated patients revealed that Group T had significantly shorter PFS (p < 0.001), and all recurrence patterns were multiple (p = 0.002). Pathological analysis in 28 surgical patients showed that serosal invasion was present in significantly more patients in Group T (p = 0.003). Conclusions: Low serum albumin levels in patients with HCC indicate both liver dysfunction and increased tumor invasion and metastasis. Nutritional support and albumin supplementation may help reduce intrahepatic metastases and improve prognosis. Further studies are needed to explore the underlying mechanisms and therapeutic potential.

10 July 2008 in EP Europace
Verified
Journal Article
Open access
PDF file
TYTakuya Yamada
Takuya Yamada
JAJeffery Scott Allison
Jeffery Scott Allison
HMHugh Thomas McElderry
Hugh Thomas McElderry
HDHarish Doppalapudi
Harish Doppalapudi
AEAndrew E. Epstein
Andrew E. Epstein
GKGeorge Neal Kay
George Neal Kay
A 31-year-old woman with idiopathic premature ventricular contractions originating from the tricuspid annulus (TA) underwent electrophysiological testing. Activation mapping with a 20-pole bipolar Halo-type catheter positioned along the TA revealed the earliest ventricular activation at a site between 7 and 8 o'clock along the TA. A reversal in the polarity of the local ventricular electrograms was observed between the two neighbouring electrode pairs of the TA catheter. Successful catheter ablation was achieved at the ventricular site between those electrode pairs. A Halo-type catheter may be effective for mapping and catheter ablation of ventricular arrhythmias originating from the TA.

1 August 2008 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SKShigeru Kiyama
Shigeru Kiyama
TYTakuya Yamada
Takuya Yamada
HIHisashi Iwata
Hisashi Iwata
TSTakafumi Sekino
Takafumi Sekino
Hiroshi MatsuoHiroshi Matsuo
Hiroshi Matsuo
HTHirofumi Takemura
Hirofumi Takemura